Solid Biosciences Inc.

NasdaqGS:SLDB Stock Report

Market Cap: US$240.6m

Solid Biosciences Balance Sheet Health

Financial Health criteria checks 6/6

Solid Biosciences has a total shareholder equity of $210.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $248.7M and $38.0M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$206.07m
EquityUS$210.72m
Total liabilitiesUS$37.97m
Total assetsUS$248.69m

Recent financial health updates

Recent updates

Buy Solid Biosciences: Unpacking Its Main Value Driver

Apr 10

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Jan 17

Solid Biosciences to acquire gene therapy company AavantiBio

Sep 30

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Apr 30
Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

Apr 28
Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Mar 17
We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

Oct 28
Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Jul 13
We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

Mar 17
We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

Soild Bio sinks 13% after Sarepta data misses goal

Jan 08

Solid Biosciences launches $90M private placement

Dec 11

Solid Biosciences: Does Not Look Like A Solid Investment Given Its Unsatisfactory Trial Data

Nov 10

Financial Position Analysis

Short Term Liabilities: SLDB's short term assets ($214.2M) exceed its short term liabilities ($14.3M).

Long Term Liabilities: SLDB's short term assets ($214.2M) exceed its long term liabilities ($23.6M).


Debt to Equity History and Analysis

Debt Level: SLDB is debt free.

Reducing Debt: SLDB has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SLDB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SLDB has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 5.4% each year.


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.